Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (834)	1/28/2002 2:11:52 PM
From: keokalani'nui	Respond to of 2243

JMarcus: >>The studies clearly indicate the advantages of using a combined treatment of Arestin(TM) plus SRP is a more effective way to eliminate the bacteria that cause periodontal disease.<< Arestin may be great therapeutic and I hope you make a killing. But there is increasing evidence that bacteria may not be the mediators, as once thought, but the consequence of PD. Very preliminary, but science is looking at inflammatory cascades, neutrofil trafficing, even correlations other chronic inlammatory diseases. ncbi.nlm.nih.gov Suggest maybe pursue Dr. Serhan's work. If you find great investment from this angle, please let me know. Wilder